Enteral administration of agar as an effective adjunct to phototherapy of neonatal hyperbilirubinemia

Phototherapy increases the biliary excretion of unconjugated bilirubin. In this form, bilirubin would be subject to enterohepatic circulation, and the true efficacy of phototherapy would be blunted. We tested the hypothesis that sequestration of lumenal unconjugated bilirubin by enteral agar administration would enhance the efficacy of phototherapy in jaundiced infants. Fifty-two infants were studied, 21 control and 31 agar-supplemented. The birth weights, sex distribution, and postnatal age at onset of phototherapy did not differ between the two groups of infants; pre- and post-phototherapy bilirubin concentrations also did not differ between the groups. The bile acid concentrations and bilirubin saturation indices were also similar. The rate of declination of the plasma bilirubin concentrations after 24 h of phototherapy was greater and significantly more uniform in the agar-supplemented infants (-1.59 +/- 2.3 versus -2.51 +/- 1.44). Stool frequencies were greater in control infants (5.5 versus 4.3 per 24 h) whereas fecal bilirubin excretions were greater in agar-supplemented infants during the second day of phototherapy (1.32 versus 3.29 mg . kg-1 . 24 h-1). Agar supplementation reduced the duration of phototherapy by 23% (37.6 +/- 3.2 versus 48.1 +/- 5.0 h).

Studies of rhenium carboxylates as antitumor agents. Part II. Antitumor studies of bis (mu-propionato) diaquotetrabromodirhenium (III) in tumor-bearing mice

The neutral, dimeric complexes of rhenium, bis (mu-carboxalato)-diaquotetrahalodirhenium (III) (carboxalato = acetato, propionato, or butyrato and halo = chloro or bromo), were synthesized and survival studies were done on mice bearing P-388 leukemia or B-16 melanoma. The complex bis (mu-propionato) diaquotetrabromodirhenium (III) proved to be the most effective in increasing the life span of the mice. The complex showed some activity against B-16, but virtually none against P-388. The complexes are all quite non-toxic.

Reduction of interference by specific IgG with a modified microtiter solid-phase radioimmunoassay to measure honeybee venom IgE

By means of monoclonal mouse anti-human IgE antibody, the microtiter solid-phase radioimmunoassay (MSPRIA) was modified to measure honeybee venom (HBV) IgE. HBV IgG was measured by MSPRIA(G) using affinity column purified goat anti-human IgG antibody and correlated with results obtained with staphylococcal protein A-SPRIA. Nonlinear specific IgE dilution curves were associated with high HBV IgG content. By serial transfer and assay of the supernatant, the interference of IgE by specific IgG could be reduced. The degree of interference was correlated with the specific IgG content. The principle of serial supernatant transfer and assay was applied to the standardization of reference HBV IgE serum, and the quantitation of HBV IgE contents in patients and controls. HBV IgE levels in patients allergic to honeybee stings correlated with the skin-test endpoint titrations. While 75% of the allergic patients were skin-test positive, 83% of them were IgE positive by the MSPRIA and 67% were IgE positive by the RAST.

Honey bee venom specific immunoglobulin G4 in honey bee sting allergic patients and bee keepers

Honey bee venom (HBV) IgG4 antibody was studied in bee keepers and honey bee sting allergic patients on immunotherapy using mouse monoclonal anti-human IgG4 antibody in a modified microtiter solid phase radioimmunoassay (MSPIRA). The mean HBV IgG4 in bee keepers was 31 units/ml. In patients the mean HBV IgG4 pre- and post-immunotherapy were 2.9 and 11.6 units/ml, respectively, representing a mean rise of 7.3-fold as compared to a rise of 1.6-fold for total HBV IgG. The mean HBV IgG level in bee keepers was 14 micrograms/ml which was not significantly different from the mean level of 17 micrograms/ml in allergic patients at diagnosis. The percentage interference of HBV IgE detection in vitro correlated with HBV IgG but not with HBV IgG4. On the other hand, there was an inverse relationship between serum HBV IgE and HBV IgG4 levels while none was found for HBV IgE and IgG.

Studies on the relations of selenium and Keshan disease

Keshan disease is an endemic cardiomyopathy of unknown cause in The People's Republic of China that occurs most frequently in children under 15 years of age and women of child-bearing age. Studies of children 1-9 years old in Mianing County of Sichuan Province have indicated that Keshan disease is a selenium responsive condition. Incidence rates of 9.5-13.5/1000 in 1974-1975 were reduced to 1-2/1000 in children treated with a tablet weekly of 0.5-1 mg sodium selenite. During 1974-1977, only 21 cases of the disease occurred in 36,603 treated children, compared with 106 cases in 9430 untreated children, of whom 53 died and 5 still have insufficient heart function. Occurrence of the disease was invariably associated with a lower selenium content of cereals, and of hair (less than 0.12 ppm Se) in residents from affected, compared with non-affected, areas. The dose relationship between selenium and regional characteristics of Keshan disease suggests that it is probably a biogeochemical disease; other etiological factors have also been considered.